Research Projects Page

Oral options, such as ibrutinib, acalabrutinib, and venetoclax for CLL may have significant adverse events. Our objective was to evaluate pharmacist interventions on these adverse events at Vanderbilt Specialty Pharmacy. The majority of the pharmacist interventions were resolved and resulted in chart review and patient counseling as well as dose changes and holding medication.

The purpose of this study was to assess factors that affect time to human growth hormone (hGH) approval, utilizing an integrated specialty pharmacy model. The outcome measure was time to approval of growth hormone. Patients with Idiopathic Short Stature and those for whom insurance requires additional testing are likely to have longer access times.

This study evaluated how the integrated specialty pharmacy model successful in treating HCV in the pediatric population

This study evaluated the impact of delayed insurance approval on outcomes in patients prescribed alternate doses of biologic therapy for the treatment of IBD. Researchers found that longer time to insurance approval of a higher biologic dosing regimen was associated with an increase in C-reactive protein, an inflammatory marker, in at least 45 days after the decision to escalate dose, suggesting the longer time to approval, the less likely to see an improvement in C-reactive protein.

This study evaluated prescription cannabidiol (CBD) outcomes during the first 12 months of therapy. Many patients (37%) utilized emergency healthcare services after CBD initiation. Prescription CBD was discontinued in 31 patients due to major side effects, common side effects, and unsatisfactory response. There was no significant change in concomitant ASM use.

This study examined the association between patient characteristics and patient-reported outcomes for patients prescribed specialty medications from rheumatology or multiple sclerosis clinics in two HSSPs for 3,677 patients over 30 months. Patients reporting tolerability issues or lower perceived effectiveness were more likely to report a missed dose.

This study evaluated the rate and reasons for Primary Medication Nonadherence (PMN) to specialty oral oncology medications in Health System Specialty Pharmacies (HSSP). Multisite retrospective cohort study across 7 HSSP sites. Most patients (89%) prescribed oral oncology treatment at HSSP initiated therapy. Primary medication nonadherence was mostly due to patient decision.

This study assessed the appropriateness of the chronic inhaler regimen for patients admitted to the hospital based on clinical practice guidelines and insurance coverage.

This study evaluated reasons for and rates of primary medication nonadherence to specialty DMARDs in patients with RA referred to an integrated health systems specialty pharmacy